Schett et al. [50] presented preliminary data of the first eight patients enrolled in a phase I/II study of a CD19 CAR-T for the treatment of B cell-mediated autoimmune disease (SLE, IM, SSc). This evidence concerns the gene CD19 and systemic sclerosis.